Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 Maintenance in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT02878889Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
tegafur
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02878889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878889.